Abstract | OBJECTIVES: METHODS: We retrospectively enrolled otherwise healthy children between 1 month and 18 years of age discharged with an OAI from our institution over an 11-year period. An absolute neutrophil count (ANC) ≤1500 cells/μL was defined as neutropenia. We recorded demographic and clinical information, as well as the value and timing of each ANC in relation to changes in antibiotic therapy. A multivariable regression model assessed the contributions of various risk factors. RESULTS: A total of 186 children were enrolled (mean age, 7.6 years; 67.2% boys). β- Lactams represented 61.2% of all prescriptions. During treatment, 61 subjects (32.8%) developed neutropenia (median time to onset, 24 days). An ANC < 500 cells/μL occurred in 7 subjects (3.8%). Neutropenic subjects (mean age, 6.0 years) were significantly younger than those without neutropenia (mean age, 8.5 years) (OR = 0.86; 95% CI: 0.79-0.93; p < 0.001) and received significantly longer courses of total (89.3 vs. 55.8 days) and parenteral (24.6 vs. 19.9 days) antibiotic therapy (OR = 1.01; 95% CI: 1.01-1.02; p = 0.004 and OR = 1.02; 95% CI: 1.01-1.04; p = 0.041, respectively). Recurrent neutropenia occurred in 23.0% of all neutropenic subjects and was significantly more common in those with a longer mean duration of parenteral therapy (OR = 1.05; 95% CI: 1.02-1.09; p = 0.004.). No complications from neutropenia occurred. CONCLUSIONS:
|
Authors | Krystian Solis, Walter Dehority |
Journal | The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
(J Pediatr Pharmacol Ther)
2019 Sep-Oct
Vol. 24
Issue 5
Pg. 431-437
ISSN: 1551-6776 [Print] United States |
PMID | 31598107
(Publication Type: Journal Article)
|
Copyright | Copyright Published by the Pediatric Pharmacy Advocacy Group. All rights reserved. For permissions, email: [email protected] 2019. |